Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 785783, 12 pages
http://dx.doi.org/10.1155/2015/785783
Research Article

AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression

1Department of Molecular Genetics, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6200 MD Maastricht, Netherlands
2Department of Pharmacology and Therapeutic Chemistry, Biomedicine Institute of University of Barcelona (IBUB), Pediatric Research Institute-Sant Joan de Déu Hospital and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
3Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, “Sant Joan” University Hospital, Pere Virgili Health Research Institute (IISPV) and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Faculty of Medicine and Health Sciences, Rovira i Virgili University, Sant Llorenç 21, 4301 Reus, Spain

Received 30 July 2015; Revised 26 October 2015; Accepted 27 October 2015

Academic Editor: Shinichi Oka

Copyright © 2015 Ricardo Rodríguez-Calvo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Iliadis, N. Kadoglou, and T. Didangelos, “Insulin and the heart,” Diabetes Research and Clinical Practice, vol. 93, supplement 1, pp. S86–S91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Gray and J. K. Kim, “New insights into insulin resistance in the diabetic heart,” Trends in Endocrinology and Metabolism, vol. 22, no. 10, pp. 394–403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Huss and D. P. Kelly, “Mitochondrial energy metabolism in heart failure: a question of balance,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 547–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, “Myocardial fatty acid metabolism in health and disease,” Physiological Reviews, vol. 90, no. 1, pp. 207–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. G. Hardie, J. W. Scott, D. A. Pan, and E. R. Hudson, “Management of cellular energy by the AMP-activated protein kinase system,” FEBS Letters, vol. 546, no. 1, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. L. G. D. Fryer and D. Carling, “AMP-activated protein kinase and the metabolic syndrome,” Biochemical Society Transactions, vol. 33, no. 2, pp. 362–366, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. D. G. Hardie, “AMP-activated protein kinase: the guardian of cardiac energy status,” The Journal of Clinical Investigation, vol. 114, no. 4, pp. 465–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. V. G. Zaha and L. H. Young, “AMP-activated protein kinase regulation and biological actions in the heart,” Circulation Research, vol. 111, no. 6, pp. 800–814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Kudo, A. J. Barr, R. L. Barr, S. Desai, and G. D. Lopaschuk, “High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase,” The Journal of Biological Chemistry, vol. 270, no. 29, pp. 17513–17520, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. R.-S. Meng, Z.-H. Pei, R. Yin et al., “Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-α signaling pathway,” European Journal of Pharmacology, vol. 620, no. 1–3, pp. 63–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Meng, Z. Pei, A. Zhang et al., “AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway,” Archives of Biochemistry and Biophysics, vol. 511, no. 1-2, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. V. A. Narkar, M. Downes, R. T. Yu et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell, vol. 134, no. 3, pp. 405–415, 2008. View at Publisher · View at Google Scholar
  13. T. Haffar, F. Bérubé-Simard, and N. Bousette, “Cardiomyocyte lipotoxicity is mediated by Il-6 and causes down-regulation of PPARs,” Biochemical and Biophysical Research Communications, vol. 459, no. 1, pp. 54–59, 2015. View at Publisher · View at Google Scholar
  14. H. Lee, R. U. Kang, S. Bae, and Y. Yoon, “AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/β-catenin pathway in 3T3-L1 adipocytes,” International Journal of Molecular Medicine, vol. 28, no. 1, pp. 65–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Gilde, K. A. J. M. van der Lee, P. H. M. Willemsen et al., “Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism,” Circulation Research, vol. 92, no. 5, pp. 518–524, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Muoio, P. S. MacLean, D. B. Lang et al., “Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPARδ,” The Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089–26097, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Google Scholar
  18. J. Luo, S. Wu, J. Liu et al., “Conditional PPARγ knockout from cardiomyocytes of adult mice impairs myocardial fatty acid utilization and cardiac function,” American Journal of Translational Research, vol. 3, no. 1, pp. 61–72, 2010. View at Google Scholar · View at Scopus
  19. K. Yamamoto, R. Ohki, R. T. Lee, U. Ikeda, and K. Shimada, “Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes,” Circulation, vol. 104, no. 14, pp. 1670–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Göttlicher, E. Widmark, Q. Li, and J.-Å. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. R. R. Russell III, R. Bergeron, G. I. Shulman, and L. H. Young, “Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 277, no. 2, pp. H643–H649, 1999. View at Google Scholar · View at Scopus
  22. A. Sriwijitkamol and N. Musi, “Advances in the development of AMPK-activating compounds,” Expert Opinion on Drug Discovery, vol. 3, no. 10, pp. 1167–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. W. Schwenk, E. Dirkx, W. A. Coumans et al., “Requirement for distinct vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes,” Diabetologia, vol. 53, no. 10, pp. 2209–2219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. D. Darrabie, A. J. L. Arciniegas, R. Mishra, D. E. Bowles, D. O. Jacobs, and L. Santacruz, “AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 300, no. 5, pp. E870–E876, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. T.-I. Lee, Y.-H. Kao, Y.-C. Chen, N.-H. Pan, and Y.-J. Chen, “Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart,” European Journal of Clinical Investigation, vol. 40, no. 8, pp. 692–699, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. I. Lee, Y. H. Kao, Y. C. Chen et al., “Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes,” Clinical Science, vol. 121, no. 7, pp. 305–312, 2011. View at Google Scholar
  27. D. Abdurrachim, J. J. F. P. Luiken, K. Nicolay, J. F. C. Glatz, J. J. Prompers, and M. Nabben, “Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models,” Cardiovascular Research, vol. 106, no. 2, pp. 194–205, 2015. View at Publisher · View at Google Scholar
  28. L. Zhu, Q. Wang, L. Zhang et al., “Hypoxia induces PGC-1α expression and mitochondrial biogenesis in the myocardium of TOF patients,” Cell Research, vol. 20, no. 6, pp. 676–687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Li, L. Wu, C. Wang, L. Liu, and Y. Zhao, “Adiponectin modulates carnitine palmitoyltransferase-1 through AMPK signaling cascade in rat cardiomyocytes,” Regulatory Peptides, vol. 139, no. 1–3, pp. 72–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Fujita, N. Maeda, M. Sonoda et al., “Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 863–870, May 2008. View at Google Scholar
  31. G. Barreto-Torres, J. S. Hernandez, S. Jang et al., “The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARalpha-cyclophilin D interaction in cardiomyocytes,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 308, no. 7, pp. H749–H758, 2015. View at Publisher · View at Google Scholar
  32. K. Kajita, T. Mune, T. Ikeda et al., “Effect of fasting on PPARγ and AMPK activity in adipocytes,” Diabetes Research and Clinical Practice, vol. 81, no. 2, pp. 144–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein kinase inhibitors: a further update,” Biochemical Journal, vol. 408, no. 3, pp. 297–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. L. G. D. Fryer, A. Parbu-Patel, and D. Carling, “Protein kinase inhibitors block the stimulation of the AMP-activated protein kinase by 5-amino-4-imidazolecarboxamide riboside,” FEBS Letters, vol. 531, no. 2, pp. 189–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. M. E. Young, S. Patil, J. Ying et al., “Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor α in the adult rodent heart,” The FASEB Journal, vol. 15, no. 3, pp. 833–845, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Rodríguez-Calvo, L. Serrano, E. Barroso et al., “Peroxisome proliferator-activated receptor α down-regulation is associated with enhanced ceramide levels in age-associated cardiac hypertrophy,” Journals of Gerontology—Series A: Biological Sciences and Medical Sciences, vol. 62, no. 12, pp. 1326–1336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Bezaire, L. L. Spriet, S. Campbell et al., “Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation,” The FASEB Journal, vol. 19, no. 8, pp. 977–979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Buchanan, P. K. Mazumder, P. Hu et al., “Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity,” Endocrinology, vol. 146, no. 12, pp. 5341–5349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Xiong, H. He, J. James et al., “Cardiac-specific VLCAD deficiency induces dilated cardiomyopathy and cold intolerance,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 3, pp. H326–H338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. M. C. Kruger, M. Coetzee, M. Haag, and H. Weiler, “Long-chain polyunsaturated fatty acids: selected mechanisms of action on bone,” Progress in Lipid Research, vol. 49, no. 4, pp. 438–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. D. M. Erion and G. I. Shulman, “Diacylglycerol-mediated insulin resistance,” Nature Medicine, vol. 16, no. 4, pp. 400–402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Webster, S. O. Friedrich, A. Lochner, and B. Huisamen, “AMP kinase activation and glut4 translocation in isolated cardiomyocytes,” Cardiovascular Journal of Africa, vol. 21, no. 2, pp. 72–78, 2010. View at Google Scholar · View at Scopus